Bala Cynwyd, PANCT06222099Now EnrollingIRB Ready

Heart Failure Clinical Trial in Bala Cynwyd, PA

Access cutting-edge heart failure treatment through this clinical trial at a research site in Bala Cynwyd. Study-provided care at no cost to qualified participants.

Sponsored by Heartfelt Technologies

Quick Self-Assessment

See if you qualify for this Bala Cynwyd location

Preparing your pre-screening questions…

Expert Care in Bala Cynwyd

Access heart failure specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related heart failure treatment provided free

Apply for This Bala Cynwyd Location

Check if you qualify for this heart failure clinical trial in Bala Cynwyd, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Bala Cynwyd

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Bala Cynwyd site if eligible
  4. 4Begin participation

About This Heart Failure Study in Bala Cynwyd

This pragmatic randomized crossover trial looks at the effect(s) of using a remote patient monitoring device (Heartfelt device) with health alerts to monitor the development of peripheral edema in patients with heart failure (HF). The hypothesis is that this passive measurement method will lead to better data availability, which in turn will improve patient care and reduce hospitalizations for the management of worsening HF (HF hospitalizations, HFHs) in nonadherent participants with chronic HF. The study objectives are: * Primary objective: Establish if the Heartfelt device is safe to use and effective at reducing HFHs. * Secondary objectives: 1. Establish the effect of the Heartfelt device on data availability compared to existing remote monitoring devices. 2. Establish the effect of the Heartfelt device on HF clinical outcomes. Participants will need to: * Install the device in their home for at least a year and up to 4 additional years after. * Reply to remote patient monitoring phone calls to follow the care plans.

Sponsor: Heartfelt Technologies

Who Can Participate

Inclusion Criteria

Provision of signed and dated informed consent form (wet or digital signature)
Male or female, aged 22 to \[No maximum age\]
Diagnosed with Chronic Heart failure at least 2 months prior to randomization
Documented history of peripheral edema (edema in feet and lower legs), defined as at least one clinical mention in the medical record indicative of oedema during prior clinical assessment.
Evidence of heart failure decompensation or elevated risk of future hospitalization, defined by one or more of the following: a.Hospitalization for heart failure occurring at least once in the past 6 months or at least twice in the past 12 months; OR b.Receipt of intravenous/subcutaneous diuretic therapy for heart failure (inpatient or outpatient setting) occurring at least once in the past 6 months or at least twice in the past 12 months; OR c.Emergency department or urgent care visit for heart failure decompensation, occurring at least once in the past 6 months or at least twice in the past 12 months; OR d.Clinician assessment that the participant is at high risk of heart failure hospitalization within the next 6-12 months, based on documented recent clinical course (e.g. worsening congestion, escalating diuretic requirements, recurrent decompensation, and/or comorbidity burden).
Patients who are treated with daily diuretics.
Evidence of non-adherence defined by one or more of the following:
Participants with β‰₯180 days of historical monitoring/device data available ● Failure to collect β‰₯50% of expected days of prescribed home physiological monitoring data (e.g. weight, blood pressure, or other clinician-recommended measurements), assessed over a continuous 180-day period; OR ● Discontinuation from a remote patient monitoring/home monitoring program due to non-adherence; OR ● Failure to adhere to a prescribed home-based therapy/monitoring intervention, supported by device usage data showing \<50% of expected days of use over a continuous 180-day period.
Participants without β‰₯180 days of historical monitoring/device data available: Evidence of non-adherence may be demonstrated by low data capture over shorter windows, defined as any of the following : ● ≀2 days of monitoring data recorded for each of the most recent 4 consecutive weeks during which any remote monitoring device was continuously available in the patient's home; OR ● ≀3 days of monitoring data recorded in any consecutive 8 week period period during which any remote monitoring device was continuously available in the patient home; AND/OR
by documented non-adherence in the medical record within the last 3 years:
Historical documentation of persistent medication and/or dietary non-adherence, defined as either a clear statement of ongoing non-adherence or β‰₯2 documented instances of non-adherence concerns (including dosing and/or timing, where available); OR
Historical documentation on repeated clinical assessments indicating persistent difficulty adhering to recommended self-management activities (e.g. repeated failure to follow monitoring instructions, incomplete engagement with care plan, or repeated non-attendance at scheduled reviews).
For participants not previously enrolled in RPM or without sufficient historical monitoring data, non-adherence will be assessed prospectively using connected scales provided at study initiation. Objective adherence metrics derived from scale usage during the initial monitoring period will be used both to characterise baseline adherence and to support predefined subgroup analyses.
Clinical teams/PIs discretion as patients being non-adherent.
For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 6 weeks after the end of the study.
Patients who are covered by an insurance plan that covers IDE-B costs (e.g. Medicare Part-B), OR written contract signed by the patient, or their provider or payor, stating that they will be liable for any trial-associated costs that Medicare would ordinarily cover if the patient were covered by Medicare. 1\. Participant has bandages to lower limbs every day 2. Participant has an amputation of both feet 3. Participant is a regular wheelchair user inside their home 4. Participant is bed-bound 5. Participant is of no fixed abode 6. Participant is taking part in a conflicting evaluation/study that could confound the results of this evaluation and/or impact clinical interventions and participant outcomes 7. Participant is unable to take diuretics 8. Participant is on a regular schedule of dialysis 9. Participant has a history of recurrent leg or feet deep vein thrombosis (DVT) (two or more episodes within the last 12 months). 10\. Participant has a history of recurrent leg or feet cellulitis episodes (two or more episodes within the last 12 months). 11\. Participant is prescribed diltiazem or verapamil on an ongoing basis. 12. Participant is pregnant or is not taking medically approved birth control if of child-bearing potential.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Bala Cynwyd?

Yes, this clinical trial (NCT06222099) has an active research site in Bala Cynwyd, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Heart Failure Treatment Options in Bala Cynwyd, PA

If you're searching for heart failure treatment options in Bala Cynwyd, PA, this clinical trial (NCT06222099) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Bala Cynwyd research site is actively enrolling participants for this clinical trial. You'll receive care from experienced heart failure specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all heart failure clinical trials near you to find additional studies recruiting in your area.

More Heart Failure Trials in Bala Cynwyd, PA

See all heart failure clinical trials recruiting in Bala Cynwyd β€” not just this study.

Browse Heart Failure Trials in Bala Cynwyd β†’

Ready to Join in Bala Cynwyd?

Take the first step toward participating in this groundbreaking clinical trial

Secure Β· Expert Care Β· Bala Cynwyd, PA